KR20190109564A - 신경계 및 정신 장애의 행동 증상을 치료하는 방법 - Google Patents

신경계 및 정신 장애의 행동 증상을 치료하는 방법 Download PDF

Info

Publication number
KR20190109564A
KR20190109564A KR1020197026879A KR20197026879A KR20190109564A KR 20190109564 A KR20190109564 A KR 20190109564A KR 1020197026879 A KR1020197026879 A KR 1020197026879A KR 20197026879 A KR20197026879 A KR 20197026879A KR 20190109564 A KR20190109564 A KR 20190109564A
Authority
KR
South Korea
Prior art keywords
subject
subjects
enzyme
pharmaceutical composition
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197026879A
Other languages
English (en)
Korean (ko)
Inventor
조안 엠. 폴론
매튜 에프. 헤일
제임스 시제티
케네스 나누스
제임스 제이. 폴론
Original Assignee
큐어마크, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐어마크, 엘엘씨 filed Critical 큐어마크, 엘엘씨
Priority to KR1020207027464A priority Critical patent/KR102315761B1/ko
Publication of KR20190109564A publication Critical patent/KR20190109564A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Closures For Containers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020197026879A 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법 Ceased KR20190109564A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207027464A KR102315761B1 (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261582813P 2012-01-03 2012-01-03
US61/582,813 2012-01-03
US201261600110P 2012-02-17 2012-02-17
US61/600,110 2012-02-17
PCT/US2013/020183 WO2013103746A1 (en) 2012-01-03 2013-01-03 Methods of treating behavioral symptoms of neurological and mental disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147021425A Division KR20140107665A (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027464A Division KR102315761B1 (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20190109564A true KR20190109564A (ko) 2019-09-25

Family

ID=48745413

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197026879A Ceased KR20190109564A (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법
KR1020207027464A Active KR102315761B1 (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법
KR1020147021425A Ceased KR20140107665A (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207027464A Active KR102315761B1 (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법
KR1020147021425A Ceased KR20140107665A (ko) 2012-01-03 2013-01-03 신경계 및 정신 장애의 행동 증상을 치료하는 방법

Country Status (16)

Country Link
US (3) US20130224172A1 (enExample)
EP (1) EP2800581B1 (enExample)
JP (3) JP6796372B2 (enExample)
KR (3) KR20190109564A (enExample)
CN (2) CN104144698A (enExample)
AU (2) AU2013206890B2 (enExample)
BR (1) BR112014016557A8 (enExample)
CA (1) CA2862403C (enExample)
DK (1) DK2800581T3 (enExample)
GB (1) GB2511713B (enExample)
HK (1) HK1257360A1 (enExample)
IL (1) IL233372B (enExample)
MX (2) MX363096B (enExample)
NZ (2) NZ737957A (enExample)
RU (1) RU2654230C2 (enExample)
WO (1) WO2013103746A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
AU2016247301A1 (en) * 2015-04-14 2017-10-26 Steven Hoffman Compositions and methods for treating autism
CN105213433A (zh) * 2015-11-06 2016-01-06 王益超 一种用于治疗孤独症、复发性流产和不孕症的组合物
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11547707B2 (en) * 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US20210043106A1 (en) * 2019-08-08 2021-02-11 COGNITIVEBOTICS Technologies Pvt. Ltd. Technology based learning platform for persons having autism
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN112347257B (zh) * 2020-11-11 2024-07-09 北京嘉和海森健康科技有限公司 一种患者症状口语化标准化方法和装置
WO2023201358A2 (en) * 2022-04-15 2023-10-19 AEON Biopharma, Inc. Neurotoxin compositions for use in regulating brain temperature

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) * 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6399114B2 (en) * 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
DE10065123B4 (de) * 2000-12-28 2012-12-20 Robert Bosch Gmbh Verfahren zur Steuerung einer Diagnose eines Katalysators im Abgas eines Verbrennungsmotors
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20060115467A1 (en) * 2004-12-01 2006-06-01 Pangborn Jon B Compositions and methods for the treatment of autism
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物

Also Published As

Publication number Publication date
GB201411821D0 (en) 2014-08-13
NZ734194A (en) 2021-02-26
AU2017232048A1 (en) 2017-10-12
MX2019002669A (es) 2019-05-30
GB2511713A (en) 2014-09-10
AU2017232048B2 (en) 2019-05-02
IL233372B (en) 2019-09-26
MX363096B (es) 2019-03-08
IL233372A0 (en) 2014-08-31
MX2014008156A (es) 2015-04-13
HK1257360A1 (zh) 2019-10-18
US20210162024A1 (en) 2021-06-03
RU2654230C2 (ru) 2018-05-17
JP2015503586A (ja) 2015-02-02
KR20200113029A (ko) 2020-10-05
EP2800581A4 (en) 2015-08-12
WO2013103746A1 (en) 2013-07-11
NZ716627A (en) 2017-08-25
US20130224172A1 (en) 2013-08-29
HK1201731A1 (en) 2015-09-11
EP2800581B1 (en) 2024-05-22
CN104144698A (zh) 2014-11-12
NZ737957A (en) 2021-07-30
RU2014130165A (ru) 2016-02-27
JP6810724B2 (ja) 2021-01-06
US20260069667A1 (en) 2026-03-12
DK2800581T3 (da) 2024-06-17
CA2862403C (en) 2022-08-09
JP2019006788A (ja) 2019-01-17
EP2800581A1 (en) 2014-11-12
BR112014016557A8 (pt) 2017-07-04
CA2862403A1 (en) 2013-07-11
JP2021001222A (ja) 2021-01-07
KR20140107665A (ko) 2014-09-04
AU2013206890A1 (en) 2014-07-24
BR112014016557A2 (pt) 2017-06-13
JP6796372B2 (ja) 2020-12-09
KR102315761B1 (ko) 2021-10-20
AU2013206890B2 (en) 2017-09-28
GB2511713B (en) 2020-03-04
CN108578684A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
KR102315761B1 (ko) 신경계 및 정신 장애의 행동 증상을 치료하는 방법
NZ738140A (en) Door closure
KR102101135B1 (ko) 효소 전달 시스템, 및 제조 및 사용 방법
WO2011000773A1 (en) Testing efficacy for celiac disease
Quinteros-Fernandez Knowledge and behaviors surrounding a gluten-free diet between medically and self-diagnosed individuals
Mulargia et al. Impact of the particle size of milled wheat ingredients of wire-cut cookies on their glycaemic response: A randomised cross-over human intervention study
NZ738140B2 (en) Tau-binding antibodies
NZ734194B2 (en) Methods of treating behavioral symptoms of neurological and mental disorders
Garcia et al. Investigation of lipid digestion by fungal and porcine lipase supplementation for severe pancreatic insufficiency using the in vitro dynamic TIM model
Sharma Role of Multi-Cereal in Nutritional Strategies in Children with Autism
KR20160138365A (ko) 섭식장애 치료제로써 옥시토신의 용도
TOMC NEEDS Wellness with Dr. Jen
FOOD Efficacy and safety of gluten-free and casein-free diets proposed in children presenting with pervasive developmental disorders (autism and related syndromes)
Washnieski Gluten-free and casein-free diets as a form of alternative treatment for autism
KR20160131210A (ko) 폭식성 섭식장애 조절을 위한 옥시토신의 용도
AU2013224726A1 (en) Enzyme delivery systems and methods of preparations and use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190911

Application number text: 1020147021425

Filing date: 20140730

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191011

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191224

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200824

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200923

Application number text: 1020147021425

Filing date: 20140730